[HTML][HTML] Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

C Paya, A Humar, ED Dominguez, K Washburn… - American Journal of …, 2004 - Elsevier
We compared the efficacy and safety of valganciclovir with those of oral ganciclovir in
preventing cytomegalovirus (CMV) disease in high-risk seronegative solid organ transplant
(SOT) recipients of organs from seropositive donors (D+/R-). In this randomised, prospective,
double-blind, double-dummy study, 364 CMV D+/R-patients received valganciclovir 900 mg
once daily or oral ganciclovir 1000 mg three times a day (tid) within 10 days of transplant
and continued through 100 days. CMV disease, plasma viremia, acute graft rejection, graft …